Patents Issued in March 20, 2018
-
Patent number: 9920049Abstract: The invention provides novel compounds having the general formula: wherein R1, R2, R3, R4, R5, R6, X and Y are as described in the description and in the claims, as well as or pharmaceutically acceptable salts, or enantiomers, or diastereomers thereof. The invention also contains compositions including the compounds and methods of using the compounds.Type: GrantFiled: November 11, 2016Date of Patent: March 20, 2018Assignee: Hoffman-La Roche Inc.Inventors: Song Yang, Xingchun Han, Zhanguo Wang
-
Patent number: 9920050Abstract: A fused heterocyclic compound is provided represented by the following formula (1) or an N-oxide thereof, wherein A1 represents NR5, oxygen or sulfur, A2 and A3 represent a nitrogen atom or the like, R1 represents a C1 to C6 chain hydrocarbon group or the like, R2 represents a C1 to C6 chain hydrocarbon group or the like, R3 and R4 are the same or different and represent a C1 to C6 chain hydrocarbon group or the like, n represents 0, 1 or 2, and G represents any of the following formulae, wherein Q represents an oxygen or sulfur atom, p represents 0 or 1, and R10 to R24 are the same or different and represent a C1 to C6 chain hydrocarbon group or the like. The compound has an excellent control effect on pests.Type: GrantFiled: June 25, 2014Date of Patent: March 20, 2018Assignee: Sumitomo Chemical Company, LimitedInventors: Takamasa Tanabe, Hajime Mizuno, Ayaka Tanaka, Shinya Nishimura, Yoshihiko Nokura
-
Patent number: 9920051Abstract: Object of the present invention is an improved process for the preparation of Apixaban, through new intermediates which undergo to a faster amidation reaction. Impurities of Apixaban are also identified and quantified.Type: GrantFiled: February 18, 2015Date of Patent: March 20, 2018Assignee: F.I.S.—FABBRICA ITALIANA SINTETICI S.P.A.Inventors: Elena Brasola, Filippo Tomasi
-
Patent number: 9920052Abstract: A series of substituted 1H imidazo[4,5-c]pyridine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.Type: GrantFiled: December 8, 2014Date of Patent: March 20, 2018Assignee: UCB Biopharma SPRLInventors: Victoria Elizabeth Jackson, John Robert Porter
-
Patent number: 9920053Abstract: The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease, disorder or condition ameliorated by inhibition of a dopamine transporter); and methods of treating patients with such compounds; wherein R1, R2, R3, R4, R9a, R9b, R9c, R9d, R9e, R9f, m, n, A, L and B are as defined herein.Type: GrantFiled: September 14, 2015Date of Patent: March 20, 2018Assignee: CHRONOS THERAPEUTICS LIMITEDInventors: Susanna Cremonesi, Fabrizio Micheli, Teresa Semeraro, Luca Tarsi, Tim Luker, Colin Leslie
-
Patent number: 9920054Abstract: The present invention provides methyl- and trifluoromethyl-substituted pyrrolopyridines, pharmaceutical compositions thereof, methods of modulating ROR? activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such pyrrolopyridines and pharmaceutical compositions thereof.Type: GrantFiled: April 28, 2017Date of Patent: March 20, 2018Assignee: Pfizer Inc.Inventor: Mark Edward Schnute
-
Patent number: 9920055Abstract: Provided are certain fused tricyclic urea compounds and salts thereof, compositions thereof, and methods of use therefor.Type: GrantFiled: April 28, 2017Date of Patent: March 20, 2018Assignee: BEIGENE, LTD.Inventors: Changyou Zhou, Guoliang Zhang
-
Patent number: 9920056Abstract: The present invention provides compounds of Formula 1, where A is selected from and R1, R2 and R3 are defined in the specification, or a pharmaceutically acceptable salt thereof, methods of using the compounds to treat diabetes, and processes for the synthesis of the compounds.Type: GrantFiled: June 8, 2016Date of Patent: March 20, 2018Assignee: Eli Lilly and CompanyInventors: Thomas James Beauchamp, David Andrew Coates, Maria Angeles Martinez-Grau, Miguel Angel Toledo
-
Patent number: 9920057Abstract: Disclosed is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof as an inhibitor of phosphodiesterase type 5 and its therapeutic use in treating and/or preventing a disease or condition related with phosphodiesterase type 5 in a mammal wherein an inhibition of phosphodiesterase type 5 is considered beneficialType: GrantFiled: November 30, 2015Date of Patent: March 20, 2018Assignee: Chongqing University of Arts and SciencesInventors: Zhongzhu Chen, Zhigang Xu, Dianyong Tang
-
Patent number: 9920058Abstract: 7-(substituted) derivatives of 7H-pyrrolo[3,2-f]-quinazoline-1,3-diamines, derivative thereof, and methods of using them are provided. The pharmaceutical formulations prepared from the compounds can be used to treat a variety of conditions, which include, but are not limited to bacterial and fungal infections. The compounds can also be used as a sterilizing or disinfecting agent.Type: GrantFiled: May 5, 2014Date of Patent: March 20, 2018Assignee: Georgia Tech Research CorporationInventors: Bharath Srinivasan, Jeffrey Skolnick, Hongyi Zhou
-
Patent number: 9920059Abstract: The present application relates to novel heterocyclic compounds of the formula (I) in which G, R1, R2, Q and V have the meanings given in the description, to processes for their preparation and to their use for controlling animal pests.Type: GrantFiled: March 6, 2015Date of Patent: March 20, 2018Assignee: BAYER CROPSCIENCE AKTIENGESELLSCHAFTInventors: Silvia Cerezo-Galvez, Thomas Bretschneider, Christoph Grondal, Reiner Fischer, Martin Fuesslein, Peter Reinisch, Mehmet Gueclue, Kerstin Ilg, Peter Loesel, Olga Malsam
-
Patent number: 9920060Abstract: To provide a novel compound having a HER2 inhibitory effect and having a cytostatic effect. It is also intended to provide a medicament useful in the prevention and/or treatment of a disease involving HER2, particularly, cancer, on the basis of the HER2 inhibitory effect. The present invention provides a compound of formula (I) wherein X, Y, Z1, Z2, Z3, Z4, W, n, R1, R2, and R3 have meanings as defined in the present specification, or a salt thereof.Type: GrantFiled: April 20, 2017Date of Patent: March 20, 2018Assignee: TAIHO PHARMACEUTICAL CO., LTD.Inventors: Yuichi Kawai, Hiroki Irie, Takeshi Sagara, Kazutaka Miyadera
-
Patent number: 9920061Abstract: The invention provides substituted imidazo[1,5-a]pyrimidinyl carboxamide and related organic compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy, in a patient. Exemplary substituted imidazo[1,5-a]pyrimidinyl carboxamide compounds described herein include substituted 2-heterocyclyl-4-alkyl-imidazo[1,5-a]pyrimidine-8-carboxamide compounds and variants thereof.Type: GrantFiled: August 16, 2017Date of Patent: March 20, 2018Assignee: Lysosomal Therapeutics Inc.Inventors: Renato T. Skerlj, Elyse Marie Josee Bourque, Peter T. Lansbury
-
Patent number: 9920062Abstract: Antimicrobial compounds are provided that are polymerizable. The compounds include monomers with antimicrobial properties. The compounds have cross-linking properties and are hydrolytically stable. The compounds may be utilized in dental and/or medical applications, including dental composites, dentures, bonding agents, sealants, resins and medical devices.Type: GrantFiled: April 8, 2014Date of Patent: March 20, 2018Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical CollegeInventors: Xiaoming Xu, Stephen Costin
-
Patent number: 9920063Abstract: The present disclosure provides derivatives of melampomagnolide B (MMB), including carbonates, carbamates, thiocarbamates, ester and amide derivatives of MMB. These derivatives are useful for treating cancer in humans.Type: GrantFiled: August 30, 2016Date of Patent: March 20, 2018Assignees: BIOVENTURES, LLC, THE REGENTS OF THE UNIVERSITY OF COLORADOInventors: Shobanbabu Bommagani, Peter Crooks, Narsimha Reddy Penthala, Venumadhav Janganati, Craig T. Jordan, Jessica Ponder
-
Patent number: 9920064Abstract: The present invention addresses the problem of providing a solid catalyst capable of achieving high selectivity and high yield for isosorbide, preferably at the same time, in a dehydration reaction by which dianhydrosugar alcohol is obtained from a sugar alcohol, particularly, in a dehydration reaction by which isosorbide is obtained from sorbitol. The above-mentioned problem is solved by a solid catalyst for a dehydration reaction for preparing dianhydrosugar alcohol from sugar alcohol, said catalyst including an H-type ? zeolite having an atomic composition ratio of Si to Al (Si/Al) of more than 20.Type: GrantFiled: July 3, 2015Date of Patent: March 20, 2018Assignees: CLARIANT CATALYSTS (JAPAN) K.K., NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITYInventors: Atsushi Fukuoka, Hirokazu Kobayashi, Bo Feng, Haruka Yokoyama, Xin Chen
-
Patent number: 9920066Abstract: Compounds of formula (I) are A2B receptor antagonists: Wherein R1 is optionally substituted aryl or an optionally substituted 5- or 6-membered heteroaryl ring; R2 and R3 are independently selected from hydrogen, C1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkyl-(C1-C6)-alkyl, aryl-(C1-C6)-alkyl optionally substituted in the ring part thereof, a 5- or 6-membered monocyclic heterocyclic group optionally linked via a C1-C6 alkylene chain and optionally substituted in the ring part thereof, benzimidazol-2-yl-methyl, pyrid-3-yl-carbonyl, or (1-methyl-piperidin-4-yl)-carbonyl-methyl; or R2 and R3 taken together with the nitrogen atom to which they are attached form an optionally substituted 5- or 6-membered ring; R4 is C1-C3 alkyl, C2-C3 alkenyl, —N(—R5)—R6, or optionally substituted heteroarylmethylamino; and R5 and R6 are independently selected from hydrogen or C1-C3 alkyl; or R5 and R6 taken together with the nitrogen atom to which they are attached form an optionally substituted 4- to 6-membered saturated rinType: GrantFiled: February 20, 2017Date of Patent: March 20, 2018Assignee: Vernalis (R&D) Ltd.Inventors: Allan Jordan, Simon Bedford, Klenke Burkhard, Ian Yule, Karine Poullennec
-
Patent number: 9920067Abstract: The present invention relates to bis-thienobenzothienothiophene compounds and a process for their preparation. More in particular, the present invention relates to a new angular bis-thienobenzothienothiophene compound and the process for its preparation wherein said process comprises reacting at least one dihalogenated dithiophene compound with at least one terminal alkyne and the subsequent double annulation reaction. Said bis-thienobenzothienothiophene compounds can be appropriately functionalized and polymerized to produce electron donor compounds that can be advantageously used in the construction of photovoltaic devices or semiconductor polymers. Furthermore, said bis-thienobenzothienothiophene compounds, after functionalization, may be advantageously used as spectral converters in luminescent solar concentrators.Type: GrantFiled: December 11, 2015Date of Patent: March 20, 2018Assignee: Eni S.p.A.Inventors: Gabriele Bianchi, Giuliana Schimperna
-
Patent number: 9920068Abstract: The present invention relates to a compound or a pharmacologically acceptable salt thereof having excellent tissue non-specific alkaline phosphatase inhibitory activity. The present invention provides a compound represented by the formula (I): wherein R1 represents a hydrogen atom, an optionally substituted C1-6 alkyl group, or the like, R2 and R3 are the same or different and each represent a hydrogen atom, an optionally substituted C1-6 alkyl group, or the like, R4 and R5 are the same or different and each represent a hydrogen atom, an optionally substituted C1-6 alkyl group, or the like, R6 represents a hydrogen atom or the like, each R7 may be the same or different and may each represent an optionally substituted C1-6 alkoxy group or the like, X represents —CH?, —C(—R7)?, or —N?, and m represents 1 to 4, or a pharmacologically acceptable salt thereof.Type: GrantFiled: July 7, 2016Date of Patent: March 20, 2018Assignees: Daiichi Sankyo Company, Limited, Sanford Burnham Prebys Medical Discovery InstituteInventors: Shojiro Miyazaki, Yuko Yamamoto, Keisuke Suzuki, Masaharu Inui, Masanori Izumi, Kaori Soma, Anthony Pinkerton, Taeko Shinozaki
-
Patent number: 9920069Abstract: Compounds that specifically kill fluoroquinolone (FQ) resistant bacteria have been developed and are described herein. The FQs are the most commonly prescribed antibiotics to adults in the U.S. and thus are extremely important drugs. However, bacterial resistant to these drugs is now ubiquitous in some of the most common and deadly Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). Indeed, FQs are no longer indicated for treatment of MRSA and VRE infections because of such resistance. The compounds have specific and potent activity versus MRSA and VRE.Type: GrantFiled: March 17, 2015Date of Patent: March 20, 2018Assignee: The Board of Trustees of the University of IllinoisInventors: Paul J. Hergenrother, Elizabeth I. Parkinson, Joseph S. Bair
-
Patent number: 9920070Abstract: The present invention relates to novel spiro-oxazine analogs of Formula-I and Indolinone compounds of Formula-II or positional isomers, or stereoisomers, or derivatives, or pharmaceutically acceptable salt thereof. Formula-I Formula-II Further the invention provides transition-metal free multicomponent reaction (MCR) process for the preparation of said compounds of Formula-I and II using aryne precursor, N-substituted isatin and N-heteroaromatic compound as the nucleophile, under mild condition leading to formation of desired complex of spiro-oxazine analogs (I) and indolinone analogs (II) in high yield and selectivity.Type: GrantFiled: March 3, 2017Date of Patent: March 20, 2018Assignee: Council of Scientific & Industrial ResearchInventors: Biju Akkattu Thankappan, Anup Bhunia, Tony Roy
-
Patent number: 9920071Abstract: An object of the present invention is to provide a novel method for producing a compound, a salt thereof, or a hydrate of the compound or the salt, which is an FXa inhibitor. The object can be attained by a production method in which a production method via a compound represented by formula (1-1), etc., from a compound represented by the following formula (1-x), etc., is used for a method for producing a compound represented by the following formula (X), etc. [wherein X represents a halogen atom or the like, and R1 represents an optionally substituted phenyl group].Type: GrantFiled: February 13, 2015Date of Patent: March 20, 2018Assignee: Daiichi Sankyo Company, LimitedInventor: Tsuyoshi Ueda
-
Patent number: 9920072Abstract: The present invention provides a compound of formula (I), having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.Type: GrantFiled: October 30, 2015Date of Patent: March 20, 2018Assignee: HOFFMANN-LA ROCHE INC.Inventors: Bjoern Bartels, Cosimo Dolente, Wolfgang Guba, Wolfgang Haap, Ulrike Obst Sander, Jens-Uwe Peters, Mark Rogers-Evans, Didier Rombach, Thomas Woltering
-
Patent number: 9920073Abstract: The present invention includes novel compositions useful for preventing or treating an HIV-1 infection in a subject in need thereof. The present invention further includes a novel method of preventing or treating an HIV-1 infection in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of the invention. In certain embodiments, the subject is further administered at least one additional therapeutic agent.Type: GrantFiled: October 3, 2014Date of Patent: March 20, 2018Assignee: Drexel UniversityInventor: Simon Cocklin
-
Patent number: 9920074Abstract: The present invention relates to pharmaceutical compounds, compositions and methods, especially as they are related to compositions and methods for the treatment and/or prevention of a proliferation disorder, a cancer, a tumor, an inflammatory disease, an autoimmune disease, psoriasis, dry eye or an immunologically related disease, and in some embodiments diseases or disorders related to the dysregulation of kinase such as, but not limited to, EGFR (including HER), Alk, PDGFR, BLK, BMX/ETK, FLT3(D835Y), ITK, TEC, TXK, BTK, or JAK, and the respective pathways.Type: GrantFiled: September 20, 2016Date of Patent: March 20, 2018Assignee: ACEA BIOSCIENCES INC.Inventors: Xiao Xu, Xiaobo Wang, Long Mao, Li Zhao, Biao Xi
-
Patent number: 9920075Abstract: The present invention provides compounds of Formula (I): wherein A and R1 are each as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, which may be used as medicaments.Type: GrantFiled: September 9, 2015Date of Patent: March 20, 2018Assignee: Bristol-Myers Squibb CompanyInventors: Nicholas R. Wurtz, Andrew Quoc Viet, Scott A. Shaw, Benjamin P. Vokits, Ellen K. Kick, Meriah Neissel Valente, Andrew K. Dilger, Kumar Balashanmuga Pabbisetty, Sutjano Jusuf
-
Patent number: 9920076Abstract: Metal organic framework compositions can have a face centered cubic structure.Type: GrantFiled: October 21, 2015Date of Patent: March 20, 2018Assignee: KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGYInventors: Mohamed Eddaoudi, Dong-Xu Xue, Amy J. Cairns, Youssef Belmabkhout
-
Patent number: 9920077Abstract: Halogen free amine substituted trisilylamine and tridisilylamine compounds and a method of their preparation via de-hydrogenative coupling between the corresponding unsubstituted trisilylamines and amines catalyzed by transition metal catalysts is described. This new approach is based on the catalytic dehydrocoupling of a Si—H and a N—H moiety to form an Si—N containing compound and hydrogen gas. The process can be catalyzed by transition metal heterogenous catalysts such as Ru(0) on carbon, Pd(0) on MgO) as well as transition metal organometallic complexes that act as homogeneous catalysts. The —Si—N containing products are halide free. Such compounds can be useful for the deposition of thin films by chemical vapor deposition or atomic layer deposition of Si containing films.Type: GrantFiled: September 19, 2014Date of Patent: March 20, 2018Assignee: L'Air Liquide, SociétéAnonyme pour l'Etude et l'Exploitation des Procédés Georges ClaudeInventors: Antonio Sanchez, Jean-Marc Girard
-
Patent number: 9920078Abstract: Compounds and method of preparation of Si—X and Ge—X compounds (X?N, P, As and Sb) via dehydrogenative coupling between the corresponding unsubstituted silanes and amines (including ammonia) or phosphines catalyzed by metallic catalysts is described. This new approach is based on the catalytic dehydrogenative coupling of a Si—H and a X—H moiety to form a Si—X containing compound and hydrogen gas (X?N, P, As and Sb). The process can be catalyzed by transition metal heterogenous catalysts such as Ru(0) on carbon, Pd(0) on MgO) as well as transition metal organometallic complexes that act as homogeneous catalysts. The —Si—X products produced by dehydrogenative coupling are inherently halogen free. Said compounds can be useful for the deposition of thin films by chemical vapor deposition or atomic layer deposition of Si-containing films.Type: GrantFiled: August 24, 2016Date of Patent: March 20, 2018Assignee: L'Air Liquide, Société Anonyme pour l'Etude et l'Exploitation des Procédés Georges ClaudeInventors: Antonio Sanchez, Gennadiy Itov, Peng Zhang, Matthew Damien Stephens, Manish Khandelwal
-
Patent number: 9920079Abstract: A process for preparing a reaction product including a halosilane includes: contacting an unsaturated hydrocarbyl halide and a ternary intermetallic compound at a temperature of 300° C. to 700° C. to form the reaction product. The ternary intermetallic compound includes copper, silicon and a transition metal. The halosilane in the reaction product has formula R1mR2n—HoSiX(4?m?n?o)> where each R1 is independently a saturated monovalent hydrocarbyl group, each R2 is independently an unsaturated monovalent hydrocarbyl group; each X is independently a halogen atom; subscript m is 1, 2, or 3; subscript n is 0, 1, or 2; subscript o is 0, 1, or 2; and a quantity (m+n+o) is 1, 2, or 3. At least a portion of the unsaturated hydrocarbyl groups in the unsaturated hydrocarbyl halide are converted to saturated hydrocarbyl groups (R1) in the halosilane.Type: GrantFiled: November 6, 2015Date of Patent: March 20, 2018Assignee: Dow Corning CorporationInventors: Dimitris Katsoulis, John Roberts
-
Patent number: 9920080Abstract: Provided is an alkoxysilyl-vinylene group-containing silicon compound represented by the following general formula (1): wherein each of R1 and R2 independently represents a monovalent hydrocarbon group having 1 to 20 carbon atoms; R represents a monovalent hydrocarbon group having an organic functional group(s) and 1 to 30 carbon atoms; and n represents an integer of 1 to 3. The alkoxy groups in the novel organic silicon compound of the invention have a dramatically improved hydrolyzability. Further, a high adhesion or adhesiveness; and a fast adhesiveness can be exhibited by adding the novel organic silicon compound to a room temperature curable organopolysiloxane.Type: GrantFiled: February 2, 2015Date of Patent: March 20, 2018Assignee: Shin-Etsu Chemical Co., Ltd.Inventors: Akira Uta, Akitsugu Fujiwara, Takafumi Sakamoto
-
Patent number: 9920081Abstract: The present invention relates to halogen-free oligomer mixtures of poly(alkylene phosphates), production of these and use as flame retardants, and also to flame-retardant polyurethanes comprising halogen-free oligomer mixtures as flame retardants.Type: GrantFiled: July 15, 2013Date of Patent: March 20, 2018Assignee: LANXESS Deutschland GmbHInventors: Jan-Gerd Hansel, Heiko Tebbe
-
Patent number: 9920082Abstract: The invention relates to complexing agents of formula (I): in which A, chrom1, chrom2 and chrom3 are as defined in the description. The invention also relates to the lanthanide complexes obtained from these complexing agents.Type: GrantFiled: January 16, 2014Date of Patent: March 20, 2018Assignee: CISBO BIOASSAYSInventors: Laurent Lamarque, David Parker, Stephen J. Butler, Martina Delbianco
-
Patent number: 9920083Abstract: The image recording paper medium contains at least one kind of organic phosphorus compound selected from an organic phosphonic acid represented by the following Formula (1), a salt thereof, an organic phosphoric acid represented by the following Formula (2), and a salt thereof. In the formulae, each of R1 and R2 independently represents an unsubstituted alkyl group, an unsubstituted cycloalkyl group, an unsubstituted alkenyl group, or an aryl group.Type: GrantFiled: February 9, 2016Date of Patent: March 20, 2018Assignee: FUJIFILM CorporationInventors: Wataru Kikuchi, Yuji Yoshida, Ryuji Shinohara
-
Patent number: 9920084Abstract: The invention relates to the chemical synthesis of oligonucleotides, e.g., oligoribonucleotides. In another aspect, the invention relates to compounds of formula (II) processes for making these compounds, and the use thereof in the chemical synthesis of oligonucleotides, e.g., oligoribonucleotides. The invention also relates to methods of synthesis of oligomers, including but not limited to oligopeptides, oligosaccharides and oligonucleotides, particularly oligoribonucleotides and also oligodeoxyribonucleotides, in solution systems, and ionic tag linkers for use in methods provided herein.Type: GrantFiled: August 23, 2012Date of Patent: March 20, 2018Assignees: The Royal Institution for the Advancement of Learning/McGill University, Hong Kong Polytechnic UniversityInventors: Masad J. Damha, Matthew Hassler, Tak-Hang Chan, Mallikarjuna Reddy Nandyala, Robert Alexander Donga
-
Patent number: 9920085Abstract: Oligonucleotide analogs comprising boronic acid and/or boronic ester moieties are provided. The disclosed compounds are useful for the treatment of diseases where inhibition of protein expression or correction of aberrant mRNA splice products produces beneficial therapeutic effects.Type: GrantFiled: March 7, 2013Date of Patent: March 20, 2018Assignee: SAREPTA THERAPEUTICS, INC.Inventor: Gunnar J. Hanson
-
Patent number: 9920086Abstract: The present invention relates to novel Ruthenium-based complex compounds which represent viable catalysts, in particular for all sorts of metathesis reactions. Such complex compounds can be prepared by a novel, very favorable and cost efficient method which includes the introduction of an alkylidene ligand into the complex by using vinyl sulfides or vinyl ethers.Type: GrantFiled: May 20, 2014Date of Patent: March 20, 2018Assignees: ARLANXEO DE GMBH, THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTOInventors: Douglas Wade Stephan, Clinton Lund, Michael Sgro, Fatme Dahcheh, Christopher Ong
-
Patent number: 9920087Abstract: The invention relates to the use of compounds of formulae (I) and/or (II) as colorless IR absorbers wherein M is Ni, Pd, Pt, Au, Ir, Fe, Zn, W, Cu, Mo, In, Mn, Co, Mg, V, Cr or Ti, X1, X2 and X3 are each independently of the others sulfur or oxygen, R1, R2, R3, R4, R5 and R6 are each independently of the others hydrogen, NR7R8, unsubstituted or substituted C1-C18alkyl, C1-C18 alkyl wherein the alkylene chain is interrupted with oxygen, unsubstituted or substituted C1-C18alkenyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl or unsubstituted or substituted heteroarylalkyl, R7 and R8, each independently of the other, being unsubstituted or substituted C1-C18alkyl, unsubstituted or substituted aryl, unsubstituted or substituted arylalkyl or unsubstituted or substituted heteroarylalkyl, a further IR absorber optionally being added to the compounds of formulae (I) and (II).Type: GrantFiled: June 15, 2017Date of Patent: March 20, 2018Assignee: BASF SEInventors: Urs Lehmann, Daniel Heizler
-
Patent number: 9920088Abstract: The present invention relates to the use of triterpenoid derivatives for the preparation of a medicament for preventing or treating influenza diseases, in which the substituents are as defined in the specification. The triterpenoid derivatives of the present invention have obvious inhibition effect on influenza virus, and are capable of obviously preventing influenza virus from entering cells, and can be used for preventing or treating influenza.Type: GrantFiled: October 18, 2013Date of Patent: March 20, 2018Assignee: University of MacaoInventors: Demin Zhou, Maorong Yu, Sulong Xiao, Fei Yu, Yiyun Peng, Yunyan Qiu, Lihe Zhang, Yitao Wang
-
Patent number: 9920089Abstract: The present invention relates to a process for the preparation of 17-substituted steroids and, more particularly, to an improved method of preparing micro size abiraterone or derivatives thereof in high yield and purity by means of a spherical agglomeration process.Type: GrantFiled: April 11, 2014Date of Patent: March 20, 2018Assignee: ZACH SYSTEMInventors: Patricia Poirier, Yvon Derrien, Massimiliano Forcato, Livius Cotarca, Pierrick Morice
-
Patent number: 9920090Abstract: Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, betulinic acid derivaties that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formulas I, II and III: These compounds are useful for the treatment of HIV and AIDS.Type: GrantFiled: June 17, 2015Date of Patent: March 20, 2018Assignee: ViiV HEALTHCARE UK (NO.5) LIMITEDInventors: Alicia Regueiro-Ren, Animesh Goswami, Zhiwei Guo, Thomas P. Tully, Jacob Swidorski, Zheng Liu, Nicholas A. Meanwell
-
Patent number: 9920091Abstract: A method and system for the treatment of a biomass stream to separate organic extracts/biomolecules (such as proteins, lipids and/or carotenoids) from the biomass stream, wherein the water content of the biomass stream is decreased by bringing the biomass stream into contact with a compressed liquefied gas solvent, to create a low-water content biomass stream and introducing the low-water content biomass stream to an extraction apparatus that recovers one or more organic products with little or no measurable solvent residue.Type: GrantFiled: March 13, 2017Date of Patent: March 20, 2018Assignee: Green Recovery Technologies, LLCInventors: Joseph N. Caulfield, Kenneth L. Laubsch, Bruce J. Rudin
-
Patent number: 9920092Abstract: Provided are a composition having anti-oxidant, anti-aging, and autophagy activities to thereby be useful for preventing, alleviating, or treating age-related metabolic diseases including neurodegenerative diseases or type 2 diabetes, and uses thereof.Type: GrantFiled: June 9, 2017Date of Patent: March 20, 2018Assignee: Incospharm CorporationInventors: Chae Jin Lim, Myung Ho Kor, Seok Jeong Yoon, Jin A Kim, Heung Jae Kim, Kee Don Park
-
Patent number: 9920093Abstract: Molecular mimics of Smac are capable of modulating apoptosis through their interaction with cellular IAPs (inhibitor of apoptosis proteins). The mimetics are based on a monomer or dimer of the N-terminal tetrapeptide of IAP-binding proteins, such as Smac/DIABLO, Hid, Grim and Reaper, which interact with a specific surface groove of IAP. Also disclosed are methods of using these peptidomimetics for therapeutic purposes. In various embodiments of the invention the Smac mimetics of the invention are combined with chemotherapeutic agents, including, but not limited to topoisomerase inhibitors, kinase inhibitors, NSAIDs, taxanes and platinum containing compounds use broader language.Type: GrantFiled: August 17, 2016Date of Patent: March 20, 2018Assignee: TetraLogic Birinapant UK Ltd.Inventors: Stephen M. Condon, Matthew G. Laporte, Yijun Deng, Susan R. Rippin
-
Patent number: 9920094Abstract: Affinity peptide ligands of mouse polyomavirus capsomers and a designed screening method thereof. The affinity peptide ligands can be used for separation and purification of the capsomers.Type: GrantFiled: November 10, 2014Date of Patent: March 20, 2018Assignee: TIANJIN UNIVERSITYInventors: Lin Zhang, Xiaoyan Dong, Yanying Li, Xiaodan Liu, Yan Sun
-
Patent number: 9920095Abstract: The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorder, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The gastrointestinal disorder may be classified as either irritable bowel syndrome, constipation, or excessive acidity etc. The gastrointestinal disease may be classified as either inflammatory bowel disease or other GI condition including Crohn's disease and ulcerative colitis, and cancer.Type: GrantFiled: August 20, 2015Date of Patent: March 20, 2018Assignee: SYNERGY PHARMACEUTICALS, INC.Inventors: Kunwar Shailubhai, Gary S. Jacob
-
Patent number: 9920096Abstract: The present invention relates generally to novel biological and purified peptides as bradykinin receptor modulators for use in the treatment and/or prevention of inflammatory diseases, pain, hyperalgesia, cardiovascular and/or cerebral ischemic diseases, in a subject in need thereof.Type: GrantFiled: June 24, 2014Date of Patent: March 20, 2018Inventor: Jair Ribeiro Chagas
-
Patent number: 9920097Abstract: Disclosed are capsid-modified rAAV expression vectors, as well as infectious virions, compositions, and pharmaceutical formulations that include them. Also disclosed are methods of preparing and using novel capsid-protein-mutated rAAV vector constructs in a variety of diagnostic and therapeutic applications including, inter alia, as delivery agents for diagnosis, treatment, or amelioration of one or more symptoms of disease or abnormal conditions via in situ and/or ex vivo mammalian gene therapy methods. Also disclosed are large-scale production methods for capsid-modified rAAV expression vectors, viral particles, and infectious virions having improved transduction efficiencies over those of the corresponding, un-modified, rAAV vectors, as well as use of the disclosed compositions in the manufacture of medicaments for a variety of in vitro and/or in vivo applications.Type: GrantFiled: May 21, 2013Date of Patent: March 20, 2018Assignee: University of Florida Research Foundation, IncorporatedInventors: Li Zhong, Sergei Zolotukhin, Lakshmanan Govindasamy, Mavis Agbandje-McKenna, Arun Srivastava
-
Patent number: 9920098Abstract: An object of the present invention is to develop techniques to create novel engineered protein ligands that maximize the binding capacity and binding efficiency to a target molecule of affinity separation matrices on which the protein ligands are immobilized. The present invention provides protein ligands (variants) that can be immobilized on carriers in a manner shown in schematic FIG. 1(4)-(15), as well as antibody affinity separation matrices obtained by immobilizing such a protein ligand on a water-insoluble carrier. The affinity separation matrices are characterized by their excellent binding capacity and binding efficiency to a target molecule.Type: GrantFiled: September 24, 2013Date of Patent: March 20, 2018Assignee: KANEKA CORPORATIONInventors: Shinichi Yoshida, Dai Murata, Fuminori Konoike, Keita Iguchi, Tomoyuki Nakaishi, Masahiro Hayashi
-
Patent number: 9920099Abstract: The present invention relates to a composition for preventing or treating cancer comprising Wnt decoy receptor. The composition of the present invention or the expression product thereof inhibits cancer generation, growth, proliferation and metastasis, and induces apoptosis of cancer cells, by binding to Wnt ligand and blocking ligand-receptor interactions, therefore may be effectively used as an anti-cancer agent.Type: GrantFiled: April 21, 2017Date of Patent: March 20, 2018Assignee: GENEMEDICINE CO., LTD.Inventors: Chae Ok Yun, Jung-Sun Lee